DK3046412T3 - Histidin-manipulerede letkæde-antistoffer og genetisk modificerede ikke-humane dyr til generering heraf - Google Patents

Histidin-manipulerede letkæde-antistoffer og genetisk modificerede ikke-humane dyr til generering heraf Download PDF

Info

Publication number
DK3046412T3
DK3046412T3 DK14781761.3T DK14781761T DK3046412T3 DK 3046412 T3 DK3046412 T3 DK 3046412T3 DK 14781761 T DK14781761 T DK 14781761T DK 3046412 T3 DK3046412 T3 DK 3046412T3
Authority
DK
Denmark
Prior art keywords
histidine
generation
light chain
genetically modified
chain antibodies
Prior art date
Application number
DK14781761.3T
Other languages
Danish (da)
English (en)
Inventor
John Mcwhirter
Lynn Macdonald
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/030,424 external-priority patent/US20140013456A1/en
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK3046412T3 publication Critical patent/DK3046412T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/15Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK14781761.3T 2013-09-18 2014-09-18 Histidin-manipulerede letkæde-antistoffer og genetisk modificerede ikke-humane dyr til generering heraf DK3046412T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/030,424 US20140013456A1 (en) 2012-03-16 2013-09-18 Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
PCT/US2014/056285 WO2015042250A1 (en) 2013-09-18 2014-09-18 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same

Publications (1)

Publication Number Publication Date
DK3046412T3 true DK3046412T3 (da) 2019-07-15

Family

ID=51663490

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14781761.3T DK3046412T3 (da) 2013-09-18 2014-09-18 Histidin-manipulerede letkæde-antistoffer og genetisk modificerede ikke-humane dyr til generering heraf

Country Status (25)

Country Link
EP (2) EP3046412B1 (es)
JP (3) JP6621750B2 (es)
KR (2) KR102150414B1 (es)
CN (2) CN105722387B (es)
AU (2) AU2014323527B2 (es)
BR (1) BR112016005912A2 (es)
CA (1) CA2922892C (es)
CY (1) CY1121798T1 (es)
DK (1) DK3046412T3 (es)
ES (2) ES2962489T3 (es)
HK (1) HK1225913A1 (es)
HR (1) HRP20191233T1 (es)
HU (1) HUE044747T2 (es)
IL (2) IL244226B (es)
LT (1) LT3046412T (es)
MX (1) MX362904B (es)
MY (1) MY191512A (es)
PL (1) PL3046412T3 (es)
PT (1) PT3046412T (es)
RS (1) RS59003B1 (es)
RU (2) RU2019121863A (es)
SG (2) SG11201601272YA (es)
SI (1) SI3046412T1 (es)
TR (1) TR201909967T4 (es)
WO (1) WO2015042250A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
US10919953B2 (en) 2012-08-24 2021-02-16 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific Fc region variant
EP2940135B9 (en) 2012-12-27 2021-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
US9969800B2 (en) 2015-02-05 2018-05-15 Chugai Seiyaku Kabushiki Kaisha IL-8 antibodies
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
JP2021502967A (ja) 2017-11-14 2021-02-04 中外製薬株式会社 抗C1s抗体および使用方法
EP3897117A1 (en) * 2018-12-21 2021-10-27 Compass Therapeutics LLC Transgenic mouse expressing common human light chain
CN114867345A (zh) * 2019-12-18 2022-08-05 百时美施贵宝公司 具有共同前导序列的bcr转基因小鼠
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CN114568343B (zh) * 2022-03-11 2023-04-07 成都合拓创展生物科技有限公司 制备眼病模型的头具及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PL1802193T3 (pl) 2004-10-19 2014-09-30 Regeneron Pharma Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej
CA2638774C (en) * 2006-03-31 2015-11-24 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
PL2275443T3 (pl) 2008-04-11 2016-05-31 Chugai Pharmaceutical Co Ltd Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
US20110313134A1 (en) * 2008-11-06 2011-12-22 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
MX342623B (es) 2009-06-26 2016-10-06 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
BR112012001075B1 (pt) 2009-07-16 2020-12-01 Wageningen Universiteit Métodos para mudar a capacidade de uma planta para a adaptação para mudanças na concentração de zinco no ambiente, para fitorremediação e biofortificação, bem como uso de um nucleotídeo que codifica uma proteína bzip19 e/ou bzip23
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
KR20120118045A (ko) * 2010-01-21 2012-10-25 옥시레인 유케이 리미티드 효모 세포 표면상에 폴리펩티드를 디스플레이하기 위한 방법들 및 조성물들
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
NZ719253A (en) 2010-02-08 2022-08-26 Regeneron Pharma Common light chain mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
BR112012022917A2 (pt) * 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
DK2480676T3 (en) * 2010-06-22 2016-06-20 Regeneron Pharma MICE EXPRESSING A HYDRIDE immunoglobulin light chain
WO2012066129A1 (en) * 2010-11-19 2012-05-24 Morphosys Ag A collection and methods for its use
WO2013046722A1 (ja) * 2011-09-30 2013-04-04 中外製薬株式会社 イオン濃度依存性結合分子ライブラリ
US20140013456A1 (en) * 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
MY185881A (en) * 2013-02-20 2021-06-14 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences

Also Published As

Publication number Publication date
EP3046412A1 (en) 2016-07-27
WO2015042250A9 (en) 2016-04-28
PL3046412T3 (pl) 2019-11-29
CA2922892A1 (en) 2015-03-26
EP3549437C0 (en) 2023-10-25
TR201909967T4 (tr) 2019-07-22
KR20160049018A (ko) 2016-05-04
MX2016003638A (es) 2016-07-21
CN111019953A (zh) 2020-04-17
MY191512A (en) 2022-06-28
JP2016533768A (ja) 2016-11-04
PT3046412T (pt) 2019-07-16
EP3046412B1 (en) 2019-04-10
BR112016005912A2 (pt) 2017-09-26
ES2738679T3 (es) 2020-01-24
CY1121798T1 (el) 2020-07-31
SI3046412T1 (sl) 2019-08-30
ES2962489T3 (es) 2024-03-19
SG10201810825YA (en) 2019-01-30
KR102150414B1 (ko) 2020-09-02
EP3549437B1 (en) 2023-10-25
WO2015042250A4 (en) 2015-05-28
KR20200103882A (ko) 2020-09-02
MX362904B (es) 2019-02-25
WO2015042250A1 (en) 2015-03-26
LT3046412T (lt) 2019-07-25
IL244226B (en) 2019-02-28
AU2021200228A1 (en) 2021-03-18
HK1225913A1 (zh) 2017-09-22
CN105722387A (zh) 2016-06-29
CN105722387B (zh) 2020-01-17
EP3549437A1 (en) 2019-10-09
JP6621750B2 (ja) 2019-12-18
IL244226A0 (en) 2016-04-21
RS59003B1 (sr) 2019-08-30
JP2020078350A (ja) 2020-05-28
CA2922892C (en) 2022-06-14
SG11201601272YA (en) 2016-03-30
RU2016114306A3 (es) 2018-04-26
RU2016114306A (ru) 2017-10-23
IL264358A (en) 2019-02-28
RU2694728C2 (ru) 2019-07-16
HRP20191233T1 (hr) 2019-10-18
AU2014323527B2 (en) 2020-10-15
AU2014323527A1 (en) 2016-04-07
HUE044747T2 (hu) 2019-11-28
RU2019121863A (ru) 2019-08-29
JP2019068850A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
DK3046412T3 (da) Histidin-manipulerede letkæde-antistoffer og genetisk modificerede ikke-humane dyr til generering heraf
IL282452B (en) Histidine-engineered light chain antibodies, and non-human animals genetically modified for their preparation
DK2989893T3 (da) Ikke-humane dyr, der udtrykker antistoffer med fælles letkæde
DK3939423T3 (da) Genetisk modificerede ikke-humane dyr og fremgangsmåder til anvendelse deraf
TR201810255T4 (tr) Modifiye edilmiş immunoglobulin ağır zincir sekanslarına sahip olan insan olmayan hayvanlar.
DK2948477T3 (da) Antistofkonstruktioner til CDH19 og CD3
DK3004162T3 (da) Anti-væg-teichoin-antistoffer og konjugater
DK3079719T3 (da) ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
DK3480215T5 (da) Anti-her2-antistof og konjugat deraf
DK2898161T3 (da) Hegn til indeslutning af dyr og fremgangsmåde til samling
DK3016547T3 (da) Dyrebarriere og fremgangsmåde
DE112014004310A5 (de) Kettenführungselement
DK3066204T3 (da) Sammensætninger og fremgangsmåder til fremstilling af genetisk modificerede dyr
DE112014004457A5 (de) Kettenführungselement
DK3074661T3 (da) Kædestrammer
DK2976253T3 (da) Kædeoverdækning og fremgangsmåde
ES2763382T8 (es) Enlace parabólico
TH148594B (th) เชนไกด์